Redburn Atlantic upgraded Charles River (CRL) to Neutral from Sell with an $188 price target The firm says demand in the company’s Discovery and Safety segment appears to have stabilized after a sustained period of weakness. Following the stock’s underperformance and with consensus much better reflecting its risks, absolute downside seems limited, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- FibroBiologics and Charles River complete master cell bank for clinical trials
- Charles River announces CAR T-cells agreement with Singapore General Hospital
- Early notable gainers among liquid option names on February 24th
- Charles River price target lowered to $179 from $182 at TD Cowen
- Cautious Outlook for Charles River Labs Amid Revenue Declines and Regulatory Concerns